- PDS Biotechnology Corporation provided a business update and financial results, including highlights on the successful clinical trial for their lead drug candidate, PDS0101, resulting in a 100% (9/9) clinical response and 89% (8/9) complete response for high-risk cervical cancer patients, and based on preliminary data, there were successful meetings with FDA to discuss the regulatory pathway for a triple combination of PDS0101, PDS0301, and an approved immune checkpoint inhibitor, but despite this, their partner Merck & Co. Inc.'s (MRK) stock was influenced by the general downward direction of the whole stock market and declined by 1.31% yesterday.
- Merck & Co.'s (MRK) stock was down 1.31% after PDS Biotechnology Corporation announced its 2022 financial results, including a net loss of approximately $40.9 million primarily due to investment in research and development, clinical programs, and the acquisition of PDS0301 from Merck KGaA.
- The article discusses the benefits of diversified dividend stocks and lists 12 stocks, including Unilever, Emerson Electric, Church & Dwight, Corning Inc., and Honeywell International, that pay regular dividends to shareholders; the article does not provide a specific reason for why Merck & Co. (MRK) stock went down.
- Merck & Co. (MRK) stock went up 2.03% after announcing that KEYTRUDA plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients with stage III-IV or recurrent endometrial carcinoma whose cancer was either mismatch repair proficient or mismatch repair deficient, according to the results from the Phase 3 NRG-GY018 trial.
- Merck & Co. (MRK) stock went up by 2.03% last night, and Aristotle Value Equity Strategy highlighted it as a top pick in their Q4 2022 investor letter, stating that it is one of the world's largest pharmaceutical firms with drugs used to treat various conditions, including oncology, vaccines, diabetes, animal health, and more.
- Merck & Co. (MRK) stock went up 2.03% last night, however, the article provided information about Aadi Bioscience, a biopharmaceutical company focused on precision therapies, and their appointment of Mohammad Hirmand, an experienced biotechnology clinical development leader and executive.
- Merck & Co. (MRK) stock went down by 0.29% last night, and the reason for the decline is not mentioned in the article, which discusses the growth potential and key insights of the global animal healthcare market.
- The stock of Merck & Co. (MRK) went down by 0.29% last night, but the article focuses on the popularity and benefits of investing in dividend aristocrats, which are companies that have raised their dividends consecutively for 25 years or more, with the article providing a list of the top 14 dividend aristocrats as of the fourth quarter of 2022, including Medtronic, Coca-Cola, Abbott Laboratories, and NextEra Energy.
- The global animal healthcare market is expected to grow at a compound annual growth rate of approximately 9.81% between 2023 and 2030, due to the increasing rate of pet ownership, but concerns around the high costs of veterinary medical care, particularly for animals that require specialist care, exist.
- Merck & Co. (MRK) announced that the US FDA approved the addition of an intramuscular (IM) route of administration to the United States Product Insert for Merck’s MMRV family of vaccines, including M-M-R®II, VARIVAX®, and ProQuad®, which resulted in the stock going up 3.95%.
- Merck & Co. (MRK) stock went up by 3.95% following the announcement of positive results from a Phase 2b clinical trial evaluating MK-0616, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in adults with hypercholesterolemia, which significantly reduced LDL-C compared to placebo and was generally well-tolerated at all 4 doses studied.
- Merck & Co.'s stock (NYSE: MRK) went up by 3.95% following the announcement of the full results from Phase 3 STELLAR trial, which demonstrated the significant efficacy of sotatercept, Merck's investigational activin signaling inhibitor biologic, in combination with stable background therapy, in treating adult patients with pulmonary arterial hypertension (PAH) (WHO Group 1), thus showing the potential of sotatercept and the approach of targeting cellular signaling associated with vascular hyperproliferation and pathological remodeling for the treatment of PAH.
- Merck & Co.'s stock went up by 3.95% after it announced that its MK-0616 oral cholesterol drug candidate significantly reduced low-density lipoprotein cholesterol in patients with hypercholesterolemia in a Phase 2b study, which showed that the drug was generally well-tolerated at all four doses.
- Merck & Co. (MRK) stock went up 3.95% as KYORIN and Sumitomo Pharma entered into a license agreement to develop, manufacture and commercialize Vibegron, a once-daily oral selective β3-adrenergic receptor agonist used to improve symptoms of overactive bladder, in Taiwan and other Asian countries, with KYORIN receiving an upfront payment and being eligible for development and sales milestone payments and royalties.
- Merck completed a cash tender offer for all of the outstanding shares of common stock of Imago BioSciences, Inc. (Nasdaq: IMGO), at a purchase price of $36.00 per share in cash, without interest and subject to deduction for any required tax withholding.
- Merck & Co. announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago BioSciences, Inc. (Nasdaq: IMGO), at a purchase price of $36.00 per share in cash, without interest and subject to deduction for any required tax withholding.
- Merck & Co. (MRK) is a pharmaceutical company that makes a variety of products, including antifungals Cresemba and Zevtera and antibiotics Ceftobiprole and Aztreonam. Their products are used to treat various kinds of infections. In 2022, Basilea Pharmaceutica Ltd., a subsidiary of Merck, reported strong sales of Cresemba and Zevtera, as well as successful in-licensing of other promising oncology and tumor-checkpoint inhibitors. These successes are likely to continue in the future.